These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 8626871)

  • 21. Dual effects of growth hormone (GH)-releasing hormone infusion in normal men: somatotroph desensitization and increase in releasable GH.
    Vance ML; Kaiser DL; Rivier J; Vale W; Thorner MO
    J Clin Endocrinol Metab; 1986 Mar; 62(3):591-4. PubMed ID: 3080467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children.
    Guzzaloni G; Grugni G; Morabito F
    Minerva Endocrinol; 1998 Dec; 23(4):99-104. PubMed ID: 10361807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH-deficient boy.
    Vance ML; Kaiser DL; Martha PM; Furlanetto R; Rivier J; Vale W; Thorner MO
    J Clin Endocrinol Metab; 1989 Jan; 68(1):22-8. PubMed ID: 2491864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nocturnal augmentation of growth hormone (GH) secretion is preserved during repetitive bolus administration of GH-releasing hormone: potential involvement of endogenous somatostatin--a clinical research center study.
    Jaffe CA; Turgeon DK; Friberg RD; Watkins PB; Barkan AL
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3321-6. PubMed ID: 7593445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discordance between growth hormone (GH) responses after GH-releasing hormone and insulin hypoglycemia in myotonic dystrophy.
    Okimura Y; Chihara K; Kita T; Kashio Y; Sato M; Kitajima N; Abe H; Takahashi K; Fujita T
    J Clin Endocrinol Metab; 1988 Nov; 67(5):1074-9. PubMed ID: 3141449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Arginine abolishes the inhibitory effect of glucose on the growth hormone response to growth hormone-releasing hormone in man.
    Ghigo E; Miola C; Aimaretti G; Valente F; Procopio M; Arvat E; Yin-Zhang W; Camanni F
    Metabolism; 1992 Sep; 41(9):1000-3. PubMed ID: 1355580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of changing somatostatin tone on the pituitary growth hormone and thyroid-stimulating hormone responses to their respective releasing factor stimuli.
    Spoudeas HA; Matthews DR; Brook CG; Hindmarsh PC
    J Clin Endocrinol Metab; 1992 Aug; 75(2):453-8. PubMed ID: 1353504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low doses of either intravenously or orally administered arginine are able to enhance growth hormone response to growth hormone releasing hormone in elderly subjects.
    Ghigo E; Ceda GP; Valcavi R; Goffi S; Zini M; Mucci M; Valenti G; Cocchi D; Müller EE; Camanni F
    J Endocrinol Invest; 1994 Feb; 17(2):113-7. PubMed ID: 8006330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence for a limited growth hormone (GH)-releasing hormone (GHRH)-releasable quantity of GH: effects of 6-hour infusions of GHRH on GH secretion in normal man.
    Vance ML; Kaiser DL; Evans WS; Thorner MO; Furlanetto R; Rivier J; Vale W; Perisutti G; Frohman LA
    J Clin Endocrinol Metab; 1985 Feb; 60(2):370-5. PubMed ID: 3917460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In obesity, glucose load loses its early inhibitory, but maintains its late stimulatory, effect on somatotrope secretion.
    Grottoli S; Procopio M; Maccario M; Zini M; Oleandri SE; Tassone F; Valcavi R; Ghigo E
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2261-5. PubMed ID: 9215304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth hormone (GH)-releasing peptide stimulation of GH release from human somatotroph adenoma cells: interaction with GH-releasing hormone, thyrotropin-releasing hormone, and octreotide.
    Renner U; Brockmeier S; Strasburger CJ; Lange M; Schopohl J; Müller OA; von Werder K; Stalla GK
    J Clin Endocrinol Metab; 1994 May; 78(5):1090-6. PubMed ID: 8175966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential effects of somatostatin (SRIH) and a SRIH analog, SMS 201-995, on the secretion of growth hormone and thyroid-stimulating hormone in man.
    Williams TC; Kelijman M; Crelin WC; Downs TR; Frohman LA
    J Clin Endocrinol Metab; 1988 Jan; 66(1):39-45. PubMed ID: 2891721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth hormone-releasing hormone infusion in patients with active acromegaly.
    Losa M; Chiodini PG; Liuzzi A; König A; Müller OA; Schopohl J; von Werder K
    J Clin Endocrinol Metab; 1986 Jul; 63(1):88-93. PubMed ID: 3086362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arginine normalizes the growth hormone (GH) response to GH-releasing hormone in adult patients receiving chronic daily immunosuppressive glucocorticoid therapy.
    Giustina A; Bossoni S; Bodini C; Girelli A; Balestrieri GP; Pizzocolo G; Wehrenberg WB
    J Clin Endocrinol Metab; 1992 Jun; 74(6):1301-5. PubMed ID: 1592874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypothalamic somatostatin mediates the suppression of growth hormone secretion by centrally administered thyrotropin-releasing hormone in conscious rats.
    Katakami H; Arimura A; Frohman LA
    Endocrinology; 1985 Sep; 117(3):1139-44. PubMed ID: 2862016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Galanin infusion partially restores the blunted growth hormone responses to repeated growth hormone releasing hormone stimuli in normal adults.
    Sartorio A; Spada A; Conti A; Grugni G; Morabito F; Faglia G
    J Endocrinol Invest; 1993 Feb; 16(2):95-8. PubMed ID: 7681861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults.
    Aimaretti G; Corneli G; Razzore P; Bellone S; Baffoni C; Arvat E; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 1998 May; 83(5):1615-8. PubMed ID: 9589665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose.
    Maccario M; Procopio M; Grottoli S; Oleandri SE; Razzore P; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3774-8. PubMed ID: 8530634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retesting young adults with childhood-onset growth hormone (GH) deficiency with GH-releasing-hormone-plus-arginine test.
    Aimaretti G; Baffoni C; Bellone S; Di Vito L; Corneli G; Arvat E; Benso L; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3693-9. PubMed ID: 11061526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.